SCHEMBL6802933

SCHEMBL6802933

CCc1ccc(C2CCN(CCCCNC(=O)c3ccc(NC(=O)c4ccc(Cl)cc4)cc3)CC2)c(OP(=O)(O)OC(C)CC)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.44
CCR2 P41597 1/20 0.40
DRD2 P14416 7/20 0.39
DRD3 P35462 4/20 0.39
DRD4 P21917 4/20 0.39
DRD1 P21728 1/20 0.39
MCHR1 Q99705 1/20 0.38
KDM4E B2RXH2 1/20 0.38
CACNA1G O43497 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
NTSR1 P30989 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ACKR3 P25106 1/20 0.38
CCR5 P51681 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6807067 0.93 SLC2A1 (0.44) SLC2A1CCR2DRD2DRD3DRD4
SCHEMBL6802923 0.87 SLC2A1 (0.48) SLC2A1CCR2DRD2DRD3DRD4
SCHEMBL3121723 0.86 DRD2 (0.51) SLC2A1DRD2DRD3DRD4DRD1
SCHEMBL3123342 0.85 SLC2A1 (0.50) SLC2A1CCR2DRD2DRD3DRD4
SCHEMBL6805753 0.85 SLC2A1 (0.49) SLC2A1CCR2DRD2DRD3DRD4
SCHEMBL3120197 0.80 LMNA (0.49) SLC2A1CCR2DRD2DRD3DRD4
SCHEMBL3120446 0.80 DRD2 (0.51) SLC2A1DRD2DRD3DRD4DRD1
SCHEMBL6807063 0.80 SLC2A1 (0.48) SLC2A1CCR2DRD2DRD3DRD4
SCHEMBL6811489 0.80 SLC6A4 (0.36) DRD2DRD3DRD4DRD1MCHR1
SCHEMBL6661963 0.78 SLC2A1 (0.50) SLC2A1CCR2DRD2DRD3DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040072865-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression SMITHKLINE BEECHAM CORPORATION 2004-04-15 US claimed
US-20040072865-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression SMITHKLINE BEECHAM CORPORATION 2004-04-15 US disclosed
EP-1351935-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2003-10-15 EP disclosed
WO-2002055495-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072865-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression NR1H2, NR1H3, NR1H4 SLC2A1 345/4885CCR2 228/4885DRD2 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.